Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights:
- Global Nanoparticle Drug Delivery Market Opportunity > USD 300 Billion by 2028
- Nanoparticle Drug Deliver Price & Dosage Insight By Therapeutic (Cancer, Anemia, Autoimmune Diseases, Neurological Disorders)
- Nanoparticle Therapeutics Approved Drugs Sales Analysis & Forecast Till 2028
- Global Nanoparticle Drugs Clinical Pipeline Insight By Phase, Company & Indication
- Nanoparticle Drug Delivery – Market Trend & Patent Distribution Analysis
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646380145
Despite huge advancement in the field of medical science and technology, cancer still remains a disease with limited number of therapeutic approaches. Currently, the research is mainly focused on the development of therapies which can overcome the limitations of conventional therapies and thus increasing survival rates in patients. In past few years, nanoparticles (1-100nm) have gained considerable interest in the development of novel approaches attributing mainly to their small size and increase surface area. Several nanoparticle based platforms have been studied including liposome, gold, silica, carbon and others.
Nanotechnology has shown promising results in enhancing chemotherapy and reducing the side effects by guiding drugs to selectively target the cancer cells. Furthermore, it also guides the surgical resection of tumors with high level of accuracy and enhances efficacy of radiotherapies and other treatment options. The development of nanoparticle system is mainly done to improve the pharmacokinetics of the drug and reduce the related toxicities. In addition to drug delivery, research has also been progressed for expanding the use of nanoparticles in the early detection of cancer. As a result, nanoparticles facilitate combination of drug delivery, multi-modality treatment, and theranostic action, thus opening new avenues for the researchers.
As of now a cocktail of nanoparticle based drugs have been approved for the management of cancer including Doxil, Hensify, Pacilal, Abraxane, Marqibo and others. These drugs have shown promising clinical outcomes in cancer patients and have shown high adoption rates in the global market owing to their reduced side-effects and high specificity towards cancer cell. Apart from this, researchers have also developed a robust clinical pipeline of nanoparticle based drugs such as CRLX101, CPI-100, BIND-014, AZD2811 and others which are present in clinical trials and have shown promising results in the management of cancer. The approval of these drugs during the forecast period is also expected to boost the growth of overall market.
Although these drugs have shown high efficacy and significant survival rates in cancer patients, the overall market will mainly be restricted by the high cost of therapy and stringent regulatory guidelines. However, the patent expiry of these drugs open opportunities for the development of generic drugs which have the potential to lower the cost of therapy, thus increasing access to large number of patients. Apart from this, the looming patent expiry of drug increasing competition among pharmaceutical companies for the development of generic drugs and increase their revenue in the global market.
As per our report findings, the global cancer nanoparticle market is anticipated to surpass US$ 300 Billion by 2028. Growing government support and funds and the rising need for requirements for novel targeted therapies is driving the growth of global cancer nanoparticle market. Furthermore, growing application of nanomaterials as nanocapsules or nanotubes in drug delivery systems, a growing prevalence of cancer and increasing investments are also boosting the growth of market. The tok key players in the global cancer nanoparticles market are AstraZeneca, Constellatin Pharmaceuticals, Celgene, Pfizer and Nanospectra Biosciences. As per region, US are expected to dominate the market due to high adoption rates of drugs and the high concentration of pharmaceutical sector in the region. Apart from this, Asia-Pacific is expected to witness highest CAGR rates due to increase in awareness among population, increase prevalence of cancer and presence of un-tapped opportunities in the region.